ARS Pharmaceuticals, Inc. (SPRY) Misses Q1 EPS by 1c

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) reported Q1 EPS of ($0.35), $0.01 worse than the analyst estimate of ($0.34). Revenue for the quarter came in at $7.97 million versus the consensus estimate of $7.48 million.

For earnings history and earnings-related data on ARS Pharmaceuticals, Inc. (SPRY) click here.

You May Also Be Interested In

• Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Bloom Energy Corporation (NYSE: BE); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: PODD): Grabar Law Offic
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery